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Guidelines and Guidance
Background
Tuberculosis (TB) remains a significant global health 
problem, responsible for an estimated 1.7 million deaths 
per year worldwide [1]. Resistance to anti-tuberculosis drugs 
is an important threat to tuberculosis control. The risk of 
treatment failure and death with standard short-course 
chemotherapy is highest with resistance to both isoniazid 
and rifampicin (multidrug-resistant tuberculosis, or MDR-
TB; see Glossary) [2]. Drug-resistant tuberculosis is “human-
made”: it results from treatment with inadequate drugs or 
drug regimens, improper case management, and preventable 
transmission. Its presence generally reflects weak tuberculosis 
control in the past or present. Between 1994–2007, resistance 
to any first-line drugs among new tuberculosis cases was 
reported from 127 settings included in the Global Project 
on Anti-Tuberculosis Drug Resistance Surveillance, with a 
median prevalence of 17% [3]. The total number of MDR-
TB cases estimated to have occurred worldwide in 2006 was 
489,139, or 4.8% of all TB cases. [3]. 
MDR-TB treatment using currently available second-line 
drugs may cure only 65%–75% of patients [4]. These drugs 
are more expensive, less potent, and less well tolerated than 
first-line drugs [4]. Inadequate treatment with second-line 
drugs may result in extensively drug-resistant tuberculosis 
(XDR-TB; see Glossary) [5,6]. XDR-TB is associated with 
high fatality, especially in patients who are co-infected with 
HIV [5,7]. In affluent countries, treatment with second-line 
drugs is generally limited to centers with specialized services. 
Such services are unavailable in many countries, and a 
programmatic approach is needed to provide treatment to 
large numbers of MDR-TB patients. 
In 1999, the World Health Organization (WHO) and 
partner agencies launched DOTS-Plus, a complementary 
DOTS-based strategy with provisions for treating MDR-TB 
based on the five tenets of the DOTS (directly observed 
treatment, short-course) strategy: sustained political 
commitment; a rational case-finding strategy; use of second-
line drugs under appropriate case management conditions; 
an uninterrupted supply of quality-assured drugs; and 
standardized recording and reporting [8]. DOTS-plus pilot 
projects were started to obtain an evidence base for this 
strategy. 
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Summary Points
sÈ 4HEÈ7ORLDÈ(EALTHÈ/RGANIZATIONÈCALLSÈFORÈMASSIVEÈSCALEUPÈOFÈ
programmatic management of drug-resistant tuberculosis in 
resource-limited settings. 
sÈ 3EVERALÈTECHNICALÈANDÈOPERATIONALÈBARRIERSÈIMPEDEÈTHEÈ
achievement of this scale-up. 
sÈ !ÈRESEARCHÈAGENDAÈDEVELOPEDÈBYÈTHEÈ3TOPÈ4"È0ARTNERSHIPÈ
identifies the most important barriers and prioritizes the 
research questions to be addressed in order to overcome these 
barriers.
sÈ 2ESEARCHÈPRIORITIESÈINCLUDEÈNEWÈANDÈIMPROVEDÈTOOLSÈFORÈDRUGÈ
resistance testing; clinical trials of simplified and shorter 
second-line treatment regimens; new and improved strategies 
for diagnosis of drug-resistant tuberculosis, treatment 
adherence, and infection control; understanding of the 
geographic variations in occurrence of drug resistance; and 
clinical trials of prophylactic treatment of contacts of patients 
with drug-resistant tuberculosis.
The Guidelines and Guidance section contains advice on conducting and reporting 
medical research.
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Concurrently, the Green Light Committee (GLC) was 
established by the Stop TB Partnership to facilitate access 
to concessionally priced, quality-assured second-line anti-
tuberculosis drugs for MDR-TB management projects that 
meet the criteria for rational use [9,10]. Evaluation of the 
first GLC-endorsed pilot projects of MDR-TB management 
in five resource-limited countries showed treatment success 
rates of 59%–83% [11]. Based on the experiences from the 
DOTS-Plus pilot projects, the WHO recently issued guidelines 
for what is now called programmatic management of drug-
resistant TB (PMDT). Funding for MDR-TB treatment has 
dramatically increased in the past few years, and is available 
through governments and donors, including the Global Fund 
to Fight AIDS, Tuberculosis and Malaria, and UNITAID. Now 
that the effectiveness and feasibility of MDR-TB management 
in resource-limited settings has been demonstrated, the 
emerging global MDR-TB epidemic requires moving beyond 
the pilot project stage in order to mainstream MDR-TB 
management into national tuberculosis control programs. 
Currently, fewer than 2% of all estimated MDR-TB patients 
receive appropriate treatment [1]. The Global Plan to 
Stop TB 2006–2015 urges a dramatic scale-up of MDR-TB 
treatment as a routine component of TB control; a 2007 
addendum calls for the treatment of 1.6 million MDR-TB 
patients by 2015 [12,13]. 
Although much has been learned from the DOTS-Plus 
pilot projects, important knowledge gaps remain to be filled 
before MDR-TB management can be mainstreamed and 
fully integrated into TB control programs in resource-limited 
settings. An earlier research agenda that addresses these gaps 
was proposed in 2001, focusing on operational questions 
surrounding these pilots [14]. Although a number of these 
questions have been answered, providing part of the evidence 
base for the WHO’s Guidelines for the Programmatic 
Management of Drug-Resistant Tuberculosis [11,15–25], 
many have not. Biological and clinical issues underlying these 
operational questions needed to be addressed first, and the 
initial agenda focused largely on research to be done as part 
of the DOT-Plus pilot projects. To facilitate and inform rapid 
scale-up, additional questions have become urgent. 
The Working Group on MDR-TB involves most stakeholder 
institutions, academics, agencies, and experts active in 
management of drug-resistant tuberculosis. It has called for 
a revised and extended research agenda that identifies the 
key research questions to be answered in order to scale up 
the management of drug-resistant tuberculosis programs. 
Its scope is expanded to cover all forms of drug-resistant 
tuberculosis (DR-TB), including XDR-TB. 
Process
The research agenda was prepared by the Research Subgroup 
of the Working Group, which comprises various areas of 
expertise (clinical, laboratory, epidemiology, health systems, 
program management). The Subgroup first identified the 
barriers to scaling up DR-TB management within each of 
the five tenets of DOTS: political commitment, case finding, 
treatment, drug supply, and recording and reporting. This 
process was guided by the WHO PMDT guidelines, which 
are based on a critical appraisal of the existing evidence 
and had been recently issued [16]. For each component, 
Glossary
Drug-resistant tuberculosis (DR-TB): Disease caused by a 
strain of M. tuberculosis that is resistant to any anti-tuberculosis 
drug.
Multidrug-resistant tuberculosis (MDR-TB): Disease caused 
by a strain of M. tuberculosis that is resistant to at least isoniazid 
and rifampicin [3,4]. 
Extensively drug-resistant tuberculosis (XDR-TB): Disease 
caused by a strain of M. tuberculosis that is resistant to isoniazid 
and rifampicin plus any fluoroquinolone and at least one of 
the three injectable second-line drugs (amikacin, kanamycin, 
capreomycin) [6,7].
Table 1. Research Priorities 
Priority Area Research Priorities
Laboratory support Improve laboratory methods for selection of drug regimens and of patients eligible for second-line treatment:
Standardization of DST for second-line drugssÈ
Establishment of prognostic value of in vitro mono-resistance and cross-resistance between second-line drugssÈ
Development and validation of tools for rapid detection of drug resistance, including for XDR-TBsÈ
Treatment strategies of DR-TB Identify optimal treatment protocols for DR-TB through (multicenter) clinical trials and well-designed cohort studies, with a 
focus on:
Optimal use of existing drugs: clinical efficacy of different standard and individual MDR-TB regimens across multiple sÈ
settings and against various drug resistance patterns with regard to the number and combination of second-line 
drugs needed according to DST
Efficacy of candidate drugs (including compassionate use and pipeline)sÈ
Programmatically relevant research Define and evaluate strategies for integration/scale-up of management of DR-TB into larger DOTS programs:
Algorithms for selecting patients eligible for drug susceptibility testing and second-line treatment in different sÈ
settings, including special strategies for high-risk groups and use of rapid resistance testing methods
Strategies for provision of second-line treatment in different settings, including adherence and use of incentives and sÈ
enablers
Effectiveness of existing infection control measures and strategies for selecting and implementing infection control sÈ
measures (for communities, households, and health care settings)
Epidemiology of DR-TB Identify and assess the relative importance of risk factors for DR-TB, in particular to explain variation in MDR-TB and XDR-TB 
prevalence between settings
Management of contacts of patients with DR-TB Clinical trials or well-designed cohort studies of the efficacy of several individual drugs and drug combinations in 
preventive treatment of persons presumably infected with DR-TB
doi:10.1371/journal.pmed.0050150.t001
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knowledge gaps were listed and translated into research 
topics that were further specified, grouped into logically 
focused research areas, and ranked by their priority. A draft 
was widely circulated among experts in the fields of DR-TB 
and programmatic management of tuberculosis, and their 
comments were considered and incorporated. Finally, the 
resulting agenda was discussed and endorsed during the 
annual meeting of the Working Group in Tbilisi, Georgia, 
September 2007. 
Prioritization
There is already extensive information to demonstrate 
successful models of management of DR-TB [4,11,15,16]. 
These experiences, however, need to be expanded and 
optimized to maximize their public health impact. Therefore, 
the priorities were defined as those research questions 
considered the most important to facilitate and accelerate 
scale-up of PMDT, and to maximize its public health impact, 
in line with the Global Plan to Stop TB 2006–2015 [12,13]. 
In order to rapidly scale up effective programmatic 
management of DR-TB, evidence is needed to answer the 
following questions [14]: 
How can regimens be selected (either at the program  s
or at the individual patient level) based on standardized 
and reproducible drug susceptibility testing (DST) that 
adequately reflects in vivo responsiveness to treatment? 
How can setting-specific treatment strategies be optimized  s
with respect to effectiveness, complexity (dosing, eligibility, 
duration, and monitoring of outcome and side effects), 
safety, adherence, and affordability? 
What is the minimum programmatic infrastructure needed  s
for such scale-up, in terms of laboratory and treatment 
provision, and of efficient and equitable patient selection 
and prevention of transmission to other patients and health 
care workers?
Scale-up of DR-TB would have limited epidemiological 
impact if not combined with strategies to reduce development 
and transmission of DR-TB. Therefore, the subgroup 
identified two other questions of importance: 
What are, in various settings, the relative contributions of  s
poor treatment, resistance amplification during treatment, 
and ongoing transmission to the drug resistance problem? 
How should infected contacts of DR-TB patients be  s
managed?
Research Priorities
The research agenda, therefore, focuses on the following 
five priority areas: laboratory support, treatment strategies, 
programmatic aspects, epidemiology of DR-TB, and 
management of contacts of DR-TB patients. The most urgent 
research questions within these five areas are presented 
(Table 1) and discussed. The complete agenda identifies 
several additional research topics within these five priority 
areas, as well as other areas of research (see http://www.who.
int/tb/).
Laboratory. Laboratory support, in particular for DST, is 
crucial for DR-TB management. Although DST for isoniazid 
and rifampicin generally gives reliable and reproducible 
results [26], susceptibility testing for second-line drugs does 
not [27]. The lack of standardized methodologies for second-
line DST currently compromises the clinical management 
of patients. In addition, the clinical significance of in vitro 
mono-resistance is often unclear, as is that of cross-resistance 
within classes of drugs, such as between newer and older 
generation fluoroquinolones [28,29]. These doubts about 
in vivo–in vitro correlation of drug resistance result in 
withholding effective drugs from patients, or exposing 
patients to ineffective drugs. Another major impediment 
to effective management of DR-TB is the long turnaround 
time of DST: two to four weeks for methods using liquid 
culture media, and four to 12 weeks for methods using solid 
media. Several methods for rapid detection of drug resistance 
have been, or are being, developed [30,31]. Most are for 
rifampicin and isoniazid only, and data from validation 
studies in the context of TB control programs are limited. 
Rapid methods for detection of resistance to second-line 
and other first-line drugs would improve individual patient 
treatment by allowing use of effective drug regimens from 
the start of treatment. Molecular assays would simplify 
decentralization of (second-line) DST, and are therefore 
most promising in the context of PMDT, but must be adapted 
to the field setting.  
Treatment strategies. Treatment strategies for DR-
TB lack a solid evidence base. Recommendations on 
drug regimens, specifically the number of drugs and the 
duration of treatment, as well as treatment monitoring 
criteria, are based on clinical experience in small-scale 
pilot projects [11,17,18,20,21]. Designed to provide proof 
of principle, these pilots aimed at maximum efficacy. 
They applied treatment strategies based on complex 
drug regimens tailored to the individual patient’s drug 
resistance profile (individualized regimens), long duration 
of treatment, and intensive monitoring of adverse events 
and treatment outcomes, and had rigorous approaches 
to ensuring treatment adherence [17]. For scale-up, 
feasibility, adherence, and effectiveness are all of paramount 
importance; simpler, effective strategies are needed. 
Possibilities for simplification that should be examined 
include the following: shorter treatment duration, 
fewer drugs (likely yielding fewer adverse events), more 
standardized approaches to treatment, and less intensive 
monitoring. In addition, new drugs need to be tested for 
efficacy and safety for treatment of DR-TB. Thus, there is 
a clear need for randomized controlled clinical trials and 
carefully designed cohort studies. 
Randomized controlled trials, which contributed to 
improving and shortening therapy for drug-susceptible TB 
[32,33], have almost never been undertaken for DR-TB. This 
was due to a lack of perceived epidemiological significance 
of DR-TB; lack of suitable trial sites; the heterogeneity of the 
patient population; absence of new anti-tuberculosis agents; 
and limited political will [14]. Recent progress, including 
new epidemiological evidence [3], policy changes [12], and 
advances in TB drug development [34], have improved the 
environment for embarking on trials of DR-TB treatment. 
The expansion of MDR-TB treatment programs provides 
the setting in which trials could be implemented [11]. As 
proposed recently by Mitnick et al. [35], an innovative 
randomized controlled trial design using optimized 
background therapy—used for regulatory approval of new 
antiretroviral agents—presents one tool for evaluating 
new agents in the context of heterogeneity [36–39]. Other 
designs will also be useful [40]. And, for the first time in 30 
years, several new drug classes that hold promise for DR-TB 
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treatment are under development [34]. Lastly, clinical trials 
for DR-TB may allow accelerated regulatory approval for new 
anti-tuberculosis agents.
The challenge of clinical trials among DR-TB patients is 
compounded by enormous variability in host and bacillary 
populations as well as social and environmental conditions. 
Producing valid results that are generalizable across human 
and mycobacterial populations will best be achieved through 
multi-site studies, preferably carried out in sites with a high 
burden of disease in heterogeneous populations (e.g., HIV-
infected/uninfected; chronic/ “new” DR-TB cases; high-
grade/low-grade resistance). Investment in capacity building 
will be required to conduct such trials. 
Programmatic aspects. There is a further need to evaluate 
strategies specific to the various components required for 
integration of PMDT into existing TB control programs. 
Selection of patients for DST can take place at various 
stages of the diagnosis and treatment process, e.g., when a 
patient starts treatment for a first TB episode, when a patient 
is still bacteriologically positive at the end of treatment, 
or when a patient is not cured by a subsequent treatment 
course [16]. Selection strategies should target those patients 
most at risk of having MDR-TB, including patients who 
may live far from DST facilities. This prospect is more 
promising in light of the advent of rapid resistance testing 
methods, in particular molecular assays, which have no 
rigorous requirements with regard to transport conditions 
of specimens and are becoming available for large-scale use 
[30].
Adherence to treatment for DR-TB is highly important 
for its success, but is complicated by its long duration and 
sometimes high frequency of adverse events [22–24]. Some of 
the DOTS-Plus pilot projects have reported high completion 
of treatment courses [22,23], but whether these results can 
be sustained if implemented at a large scale is unknown. 
Strategies therefore need to be developed that maximize 
treatment adherence in a sustainable way, and factors that 
affect adherence need to be studied, including the role of 
adverse events and levels of patient support. 
Another concern when moving from rigorously controlled 
pilots to routine program conditions is infection control. 
Nosocomial transmission of MDR-TB is well documented, 
in particular in the context of high HIV prevalence [41]. 
Guidelines for control of tuberculosis infection in health care 
settings have recently been revised to include settings with 
high MDR-TB and HIV prevalence [42]. However, the high 
cost of engineering controls and some personal respiratory 
protection measures generally limits their application in 
resource-limited settings, and little is known about the 
effectiveness of less costly alternatives proposed in these 
guidelines [43,44]. Even less is known about infection control 
outside health care settings, such as in households and in the 
community [45]. Thus strategies are needed for infection 
control in a variety of settings. 
Epidemiology. Preventing development and transmission 
of DR-TB is essential to effective PMDT. Although conditions 
leading to drug resistance in tuberculosis are well described, 
part of the variation in its occurrence is unexplained. In 
some areas the prevalence of DR-TB is very low with no 
increase, whereas in other areas the prevalence is high 
and/or increasing [3]. Major obstacles to understanding 
the epidemiology of DR-TB include the long generation 
time of the epidemic (it may take several decades before 
weaknesses or changes in tuberculosis control result in 
measurable changes in prevalence of drug resistance) [46]; 
the coexistence and interaction of several risk factors [47]; 
limited availability or quality of drug resistance data [3]; and 
limited quality of routine statistics. This makes it necessary 
to complement the monitoring and evaluation of routine 
activities with targeted research activities. 
More epidemiological studies are needed to identify 
areas of high and increasing levels of drug resistance, and 
to identify risk factors that lead to increasing occurrence of 
drug resistance. Risk factors to be evaluated include type 
and quality of first-line treatment supervision; access to TB 
drugs outside TB programs; infection control practices; use 
of rifampicin in the continuation phase of the treatment 
regimen of new tuberculosis patients; composition of and 
transfer to retreatment regimens; drug quality; Mycobacterium 
tuberculosis genotype; HIV prevalence; and level of use of 
antiretroviral treatment. Such analyses should help define 
the factors with the largest impact on the drug resistance 
situation, and thereby the most effective interventions. In 
addition, any intervention should be monitored for its impact 
on the drug resistance situation. 
Contacts of drug-resistant TB patients. The management 
of contacts of drug-resistant TB patients is a complex issue 
with a significant ethical dimension. Household infection 
control measures should be implemented to reduce the 
risk of transmission of resistant disease. Among household 
contacts found to be infected, the susceptibility pattern of 
the infecting strain remains unknown. In fact, data from 
observational cohorts suggest that strains isolated from 
contacts often do not have the same resistance pattern as those 
isolated from index cases [48,49]. Further, optimal treatment 
combinations and duration for preventive treatment of latent 
TB infection with resistant organisms are unknown. Standard 
isoniazid preventive therapy is considered unlikely to be 
efficacious for either MDR-TB or other isoniazid-resistant 
forms of tuberculosis [50,51]. Yet no large-scale controlled 
trials have been conducted of a preventive therapy regimen 
that could be used for contacts of patients with these resistant 
forms. The use of pyrazinamide in combination with other 
drugs as preventive therapy has been associated with high 
frequencies of liver toxicity and death [52]. Prophylaxis 
with second-line drugs has only been reported among small 
case series of contacts of patients with resistant disease [53]. 
Although toxicity is an accepted risk with treatment for 
active tuberculosis, since the alternative is death in a high 
proportion, the extent of accepted toxicity with preventive 
therapy is fundamentally different. Clinical series of infected 
contacts treated using various drug combinations, or a 
standard preventive therapy regimen based on representative 
population susceptibility profiles, may provide insights into 
drug tolerability, acceptance, and adherence. Well-designed 
preventive therapy trials should be considered in certain 
settings where MDR-TB therapy and a strong national 
program infrastructure are already in place.
Implementation
How to stimulate the implementation of this research agenda? 
Lessons can be drawn from experiences with the previous 
research agenda on DR-TB prepared in 2001 [14]. For several 
reasons, many research priorities remain unaddressed. 
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Most importantly, MDR-TB treatment was a marginalized 
intervention in 2001, perceived as necessary and possible 
in only a handful of settings. Consequently, research on 
MDR-TB was a priority of neither funding nor implementing 
agencies. Now, the magnitude and breadth of the epidemic, 
as well as illustrations of disparity in research resources [54], 
are fueling high-level interest and financial commitment 
[6,13,55]. Implementation of the research agenda was further 
hampered by the small scale of the pilots in which studies were 
to be conducted; since 2000, when the first cohort of 1,000 
patients in two settings was approved to receive treatment 
through the GLC, more than 30,000 patients in 60 settings 
have been approved for treatment by the end of 2007 [1]. The 
landscape for research is also more promising. For example, 
research capacity of the pilot sites have been enhanced 
through increased funding, and the pharmaceutical industry 
is investing in the capacity of at least a dozen sites globally to 
participate in clinical trials of MDR-TB. 
Further advocacy for funding will require development of 
study designs with budgets and timelines. Also, additional 
collaborations must be forged between treatment sites of 
drug-resistant tuberculosis and researchers. Research activities 
require coordination among these sites. Finally, evaluations of 
the various components of strategies for scaling-up of PMDT, 
such as infection control and treatment adherence, could be 
included in grants for tuberculosis program support. 
Conclusion
With increasing recognition of MDR/XDR-TB worldwide, the 
time has come to move PMDT in resource-limited settings 
beyond the limited, pilot project phase. Successful scale-up 
of PMDT and integration into existing tuberculosis control 
programs require the following: new and improved tools for 
drug resistance testing; clinical trials to test the efficacy and 
effectiveness of simplified and shorter second-line treatment 
regimens as well as of candidate second-line drugs; new and 
improved strategies for identifying patients with drug-resistant 
disease, promoting treatment adherence, and improving 
infection control; better epidemiological data to explain 
geographic variations in occurrence of drug resistance and 
to identify the greatest contributors to development of 
drug resistance in specific settings; and finally, clinical trials 
to test the efficacy and effectiveness of new regimens for 
prophylactic treatment of contacts of patients with DR-TB. 
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